FeesSafety
Pluang+

Upstream Bio plans Phase 3 trials for verekitug in severe asthma and CRSwNP in early 2027.

Company Fundamentals
10 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
Upstream Bio plans Phase 3 trials for verekitug in severe asthma and CRSwNP in early 2027.

Upstream Bio reported Q3 2026 results and announced plans to start Phase 3 trials of verekitug for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in Q1 2027. Verekitug, targeting the TSLP receptor, shows promise for best-in-class efficacy with convenient quarterly dosing. Ongoing Phase 2 trials in COPD and severe asthma extensions continue, with data expected in late 2027. The company holds $207.4 million in cash, supporting operations through 2027, but posted a net loss of $41.2 million for Q3 2026.

Upstream Bio's Q3 2026 results and clinical plans provide context for readers. For those following health stocks, 85 of 150 US health-sector stocks rose while 56 fell on Pluang. Notable movers include LFST at USD 14.81 (+1.44%), ENVB at USD 1.46 (+1.39%), and CRL at USD 358.00 (+1.32%) as of Nov 10, 2026 18:42 WIB.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
59 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
59 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
59 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
59 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App